Thao P. Le

Array ( [id] => 14485591 [patent_doc_number] => 10329564 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof [patent_app_type] => utility [patent_app_number] => 15/696172 [patent_app_country] => US [patent_app_date] => 2017-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 77 [patent_no_of_words] => 33160 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15696172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14498013 [patent_doc_number] => 20190192661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => TOPICAL FORMULATIONS BASED ON IONIC SPECIES FOR SKIN TREATMENT [patent_app_type] => utility [patent_app_number] => 16/329574 [patent_app_country] => US [patent_app_date] => 2017-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13690081 [patent_doc_number] => 20170355995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO FGF21 [patent_app_type] => utility [patent_app_number] => 15/684322 [patent_app_country] => US [patent_app_date] => 2017-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15684322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12233392 [patent_doc_number] => 20180066256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders' [patent_app_type] => utility [patent_app_number] => 15/676569 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 33669 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15676569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14439711 [patent_doc_number] => 20190177728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => MIR-127 AGENTS FOR USE IN THE TREATMENT OF RENAL FIBROSIS [patent_app_type] => utility [patent_app_number] => 16/326058 [patent_app_country] => US [patent_app_date] => 2017-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14467753 [patent_doc_number] => 20190185519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => PEPTIDE NUCLEIC ACID COMPLEX HAVING IMPROVED CELL PERMEABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 16/322965 [patent_app_country] => US [patent_app_date] => 2017-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14294937 [patent_doc_number] => 10287586 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Antisense molecules and methods for treating pathologies [patent_app_type] => utility [patent_app_number] => 15/661750 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 47 [patent_no_of_words] => 16458 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12051483 [patent_doc_number] => 20170327828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'TREATMENT OF PAR4 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO PAR4' [patent_app_type] => utility [patent_app_number] => 15/659122 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 27768 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15659122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808570 [patent_doc_number] => 20180161360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => P-ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATION [patent_app_type] => utility [patent_app_number] => 15/657083 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15657083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227423 [patent_doc_number] => 20190125884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES [patent_app_type] => utility [patent_app_number] => 15/641251 [patent_app_country] => US [patent_app_date] => 2017-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17677 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15641251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14246571 [patent_doc_number] => 10273477 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Therapeutic compositions [patent_app_type] => utility [patent_app_number] => 15/623139 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 8 [patent_no_of_words] => 119739 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14563995 [patent_doc_number] => 20190209604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/305937 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 212197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14497791 [patent_doc_number] => 20190192550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => Particles with RNA Cleaving Nucleobase Polymers and Uses for Managing Inflammatory Disorders [patent_app_type] => utility [patent_app_number] => 16/304549 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14005963 [patent_doc_number] => 10221421 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => Post-selec modification methods [patent_app_type] => utility [patent_app_number] => 15/602377 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 61 [patent_no_of_words] => 37094 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15602377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13116401 [patent_doc_number] => 10076536 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-18 [patent_title] => Oligonucleotide analogues targeting human LMNA [patent_app_type] => utility [patent_app_number] => 15/595820 [patent_app_country] => US [patent_app_date] => 2017-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 23759 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13717857 [patent_doc_number] => 20170369883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/587668 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89646 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15587668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824600 [patent_doc_number] => 20210139893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => G-QUADRUPLEX-CONTAINING ANTISENSE OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/097119 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16414731 [patent_doc_number] => 10822608 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-03 [patent_title] => Oligonucleotide analogues targeting human LMNA [patent_app_type] => utility [patent_app_number] => 16/096524 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 19468 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808266 [patent_doc_number] => 20210130819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => INCREASING RNAi EFFICIENCY THROUGH SINGLE NUCLEOTIDE MISMATCHES [patent_app_type] => utility [patent_app_number] => 16/097179 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210515 [patent_doc_number] => 20190117642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => TARGETING AMP DEAMINASE 2 FOR AMELIORATING CRAVING FOR SUGAR AND OTHER SUBSTANCES [patent_app_type] => utility [patent_app_number] => 16/093196 [patent_app_country] => US [patent_app_date] => 2017-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093196 [rel_patent_id] =>[rel_patent_doc_number] =>)